Skip to main content
Equibles

XTLB · Xtl Biopharmaceuticals Ltd · Documents

Track XTLB — free

Use XTLB with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research XTLB.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$1.70 -0.03 (-1.45%) At close · Nov 4
Rebalance outlook locked
Market Cap
$4.18M
Shares
2.46M
Volume · Nov 4 9546 Avg daily vol (3M) 8509

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $6.97M 20-F filed Jun 30, 2026
2026
Oct 14
Current report 6-K
Current report

Iris Shapira Yalon resigned from XTL Biopharmaceuticals Ltd.’s Board, effective upon her successor’s shareholder appointment or November 20, 2026, whichever comes first. The Board nominated Gilai Dolev as external director for an initial three-year term, subject to shareholder approval.

Jun 30
Annual report 20-F FY2025, ended Dec 31
Annual report for FY2025 AI summary on its way
Net loss $6.97M Diluted EPS -$0.01
2025
Apr 30
Annual report 20-F FY2024, ended Dec 31
Annual report for FY2024
Revenue $451K Net loss $1.03M Diluted EPS -$0.00
2024
Showing 1–50 of 91 documents
Key facts CIK 1023549 CUSIP 98386D406 13F (30d) 1 filings 1 filers Visit website Investor relations